scholarly journals Inverse Association of Female Hormone Replacement Therapy with Age-Related Macular Degeneration and Interactions withARMS2Polymorphisms

2010 ◽  
Vol 51 (4) ◽  
pp. 1873 ◽  
Author(s):  
Digna R. Velez Edwards ◽  
Paul Gallins ◽  
Monica Polk ◽  
Juan Ayala-Haedo ◽  
Stephen G. Schwartz ◽  
...  
Keyword(s):  
Hormone Replacement Therapy ◽  
Macular Degeneration ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Age Related Macular Degeneration ◽  
Inverse Association ◽  
Female Hormone ◽  
Age Related

scholarly journals Lutein and zeaxanthin intake and the risk of age-related macular degeneration: a systematic review and meta-analysis

2011 ◽  
Vol 107 (3) ◽  
pp. 350-359 ◽  
Author(s):  
Le Ma ◽  
Hong-Liang Dou ◽  
Yi-Qun Wu ◽  
Yang-Mu Huang ◽  
Yu-Bei Huang ◽  
...  
Keyword(s):  
Dietary Intake ◽  
Macular Degeneration ◽  
Data Extraction ◽  
Meta Analysis ◽  
Age Related Macular Degeneration ◽  
Inverse Association ◽  
Age Related ◽  
Search Data ◽  
The Relationship ◽  
Study Quality Assessment

Lutein and zeaxanthin are thought to decrease the incidence of age-related macular degeneration (AMD); however, findings have been inconsistent. We conducted a systematic literature review and meta-analysis to evaluate the relationship between dietary intake of lutein and zeaxanthin and AMD risk. Relevant studies were identified by searching five databases up to April 2010. Reference lists of articles were retrieved, and experts were contacted. Literature search, data extraction and study quality assessment were performed independently by two reviewers and results were pooled quantitatively using meta-analysis methods. The potential sources of heterogeneity and publication bias were also estimated. The search yielded six longitudinal cohort studies. The pooled relative risk (RR) for early AMD, comparing the highest with the lowest category of lutein and zeaxanthin intake, was 0·96 (95 % CI 0·78, 1·17). Dietary intake of these carotenoids was significantly related with a reduction in risk of late AMD (RR 0·74; 95 % CI 0·57, 0·97); and a statistically significant inverse association was observed between lutein and zeaxanthin intake and neovascular AMD risk (RR 0·68; 95 % CI 0·51, 0·92). The results were essentially consistent among subgroups stratified by participant characteristics. The findings of the present meta-analysis indicate that dietary lutein and zeaxanthin is not significantly associated with a reduced risk of early AMD, whereas an increase in the intake of these carotenoids may be protective against late AMD. However, additional studies are needed to confirm these relationships.

Does hormone replacement therapy in post-menopausal women have any effect upon nasal physiology?

2008 ◽  
Vol 122 (7) ◽  
pp. 707-710 ◽  
Author(s):  
D C Wild ◽  
C M Philpott ◽  
C R Wolstenholme ◽  
G E Murty
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Oral Contraceptive Pill ◽  
Life Questionnaire ◽  
Female Hormone ◽  
Menopausal Women ◽  
Nasal Physiology ◽  
Post Menopausal ◽  
Age Range

AbstractBackground:Previous studies have suggested that the female menstrual cycle, pregnancy and the oral contraceptive pill have an effect upon nasal physiology.Objectives:This study aimed to assess the effects upon nasal physiology of female hormone replacement therapy in post-menopausal women. This has not been previously studied.Methods:Twenty post-menopausal women (age range 36 to 70 years; mean age 57.0 years) underwent measurements of the nasal airway, including anterior rhinoscopy, peak nasal inspiratory flow rate, acoustic rhinometry, anterior rhinomanometry, mucociliary clearance time and rhinitis quality of life questionnaire. Measurements of nasal patency were recorded prior to commencing hormone replacement therapy and at a time point 77–195 days (mean 101.9 days) following commencement.Results:There was no statistical difference found for any of the variables, using the paired t-test (p > 0.05 for all).Conclusions:Female hormone replacement therapy has no discernable effect upon nasal physiology and should not be considered a cause of rhinitic symptoms.

scholarly journals Association of supplemental calcium and dairy milk intake with all-cause and cause-specific mortality in the UK Biobank: a prospective cohort study

2019 ◽  
Vol 123 (5) ◽  
pp. 574-582 ◽  
Author(s):  
L. C. Stasinopoulos ◽  
A. Zhou ◽  
E. Hyppönen
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Cancer Mortality ◽  
Hormone Replacement ◽  
Sensitivity Analyses ◽  
Milk Consumption ◽  
Inverse Association ◽  
Uk Biobank ◽  
Supplement Use ◽  
Increased Risk

AbstractExcessive Ca intakes have been proposed to associate with vascular calcification and a higher risk of prostate cancer. We investigated the associations of supplemental and dietary Ca intake with mortality using data from 497 828 UK Biobank participants. The average follow-up was 4·2 years and 14 255 participants died, 8297 from cancer, 2959 from CVD and 572 from respiratory disease. The use of Ca supplements and milk consumption were associated with differences in mortality in younger (≤65 years) but not in older participants (>65 years, Pinteraction ≤ 0·04 for all comparisons). Among participants <65 years, there was an inverse association between Ca supplementation (OR 0·91, 95 % CI 0·83, 0·99) and milk consumption (OR 0·93, 95 % CI 0·86, 1·00) with respect to all-cause mortality. In the same age group, milk drinkers had lower odds of cancer mortality (OR 0·89, 95 % CI 0·80, 0·98) but Ca supplement use was associated with increased odds of respiratory mortality (OR 1·69, 95 % CI 1·16, 2·74). All associations in participants aged ≥65 years were null after full adjustment. In sensitivity analyses stratified by hormone replacement therapy, Ca supplement use was associated with decreased odds of cancer mortality in users but increased risk in other women (OR 0·81, 95 % CI 0·69, 0·94 v. OR 1·17, 95 % CI 1·01, 1·35, respectively). To conclude, we saw little evidence for harm with dietary or supplemental Ca. Further studies are required to confirm the proposed interaction with hormone replacement therapy and to exclude reverse causation as a determinant in the association between Ca supplements and increased risk of respiratory diseases.

scholarly journals Perimenopause - from contraception to hormone replacement therapy

1999 ◽  
Vol 48 (1) ◽  
pp. 89-93
Author(s):  
V. P. Smetnik
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Reproductive System ◽  
Ovarian Function ◽  
Hormone Replacement ◽  
Age Related ◽  
One Year

Perimenopause is a period of age-related decline in ovarian function, mostly after age 45, including premenopause and one year after menopause or 2 years after the last independent menstruation. Menopause is the last independent menstruation due to the function of the reproductive system. The date of menopause is set retrospectively, that is, after 12 months of no menstruation. Menopause occurs on average around the age of 50.

Effect of hormone replacement therapy on age-related increase in carotid artery intima-media thickness in postmenopausal women

2000 ◽  
Vol 153 (1) ◽  
pp. 81-88 ◽  
Author(s):  
Florence A. Tremollieres ◽  
Fabienne Cigagna ◽  
Cathy Alquier ◽  
Colette Cauneille ◽  
Jean-Michel Pouilles ◽  
...  
Keyword(s):  
Hormone Replacement Therapy ◽  
Carotid Artery ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Hormone Replacement ◽  
Intima Media Thickness ◽  
Media Thickness ◽  
Age Related ◽  
Related Increase
Sign in / Sign up

Export Citation Format

Share Document